東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Resistance to aromatase inhibitors i...

Larionov, Alexey.

FindBook

Google Book

Amazon

博客來

Resistance to aromatase inhibitors in breast cancer

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Resistance to aromatase inhibitors in breast cancer/ edited by Alexey Larionov.
其他作者:	Larionov, Alexey.
出版者:	Cham :Springer International Publishing : : 2015.,
面頁冊數:	xvi, 288 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Drug Resistance. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-17972-8
ISBN:	9783319179728 (electronic bk.)

Resistance to aromatase inhibitors in breast cancer
Resistance to aromatase inhibitors in breast cancer[electronic resource] /edited by Alexey Larionov. - Cham :Springer International Publishing :2015. - xvi, 288 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.82196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

The book brings together current knowledge about molecular and clinical aspects of resistance to aromatase inhibitors (AIs) The topics and features include: The history of development and clinical role of aromatase inhibitors in breast cancer. The structure and function of aromatase gene and protein, including tissue-specific splicing and regulation of the gene, crystal structure of the enzyme, functioning of its active site and structural basis for development of new aromatase inhibitors. Experimental and pre-clinical models of resistance to aromatase inhibitors (including cell lines and xenografts) as well as methods and results of measuring oestrogen concentrations in blood and tumour tissue of breast cancer patients. Diversity of molecular mechanisms of AI resistance, including (i) ligand-independent signalling through oestrogen receptor pathway, (ii) hypersensitivity to low concentrations of oestrogens, (iii) crosstalk with non-endocrine signalling (including PI3K/mTOR, IGF, GDNF and Myc pathways), (iv) involvement of oestrogen-induced apoptosis and tissue microenvironment (including inflammatory immune cells and adipocytes) as well as (v) the role of epigenetic mechanisms and pioneering factors in ER signalling and AI resistance. Molecular markers and multi-gene signatures to predict response to AIs, clinical trials aimed at preventing or overcoming resistance by combining AIs with novel targeted agents (including AI combinations with HER2, EGFR, mTOR, PI3K, Akt, CDK4/6, FGFR, HDAC, IGF-1, Src, proteosome- and angiogenic- targeting agents) A review of the effects and clinical indications of aromatase inhibitors beyond breast cancer. Many of the chapters provide extensive historical overviews to connect current knowledge with the history and inner logic of the field. The authors' team includes world-leading experts, making the book an essential resource for scientists developing new treatments for breast cancer and for medics treating breast cancer patients with aromatase inhibitors.

ISBN: 9783319179728 (electronic bk.)

Standard No.: 10.1007/978-3-319-17972-8doiSubjects--Topical Terms:

836316
Drug Resistance.

LC Class. No.: RC271.E7

Dewey Class. No.: 616.994061

Resistance to aromatase inhibitors in breast cancer
LDR:03035nmm m2200313 m 4500 001 2001462
003 DE-He213
005 20151104161637.0
006 m d
007 cr nn 008maaau
008 151215s2015 gw s 0 eng d
020 $a 9783319179728 (electronic bk.)
020 $a 9783319179711 (paper)
024 7 $a 10.1007/978-3-319-17972-8 $2 doi
035 $a 978-3-319-17972-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.E7
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.994061 $2 23
090 $a RC271.E7 $b R433 2015
245 0 0 $a Resistance to aromatase inhibitors in breast cancer $h [electronic resource] / $c edited by Alexey Larionov.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a xvi, 288 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.8
520 $a The book brings together current knowledge about molecular and clinical aspects of resistance to aromatase inhibitors (AIs) The topics and features include: The history of development and clinical role of aromatase inhibitors in breast cancer. The structure and function of aromatase gene and protein, including tissue-specific splicing and regulation of the gene, crystal structure of the enzyme, functioning of its active site and structural basis for development of new aromatase inhibitors. Experimental and pre-clinical models of resistance to aromatase inhibitors (including cell lines and xenografts) as well as methods and results of measuring oestrogen concentrations in blood and tumour tissue of breast cancer patients. Diversity of molecular mechanisms of AI resistance, including (i) ligand-independent signalling through oestrogen receptor pathway, (ii) hypersensitivity to low concentrations of oestrogens, (iii) crosstalk with non-endocrine signalling (including PI3K/mTOR, IGF, GDNF and Myc pathways), (iv) involvement of oestrogen-induced apoptosis and tissue microenvironment (including inflammatory immune cells and adipocytes) as well as (v) the role of epigenetic mechanisms and pioneering factors in ER signalling and AI resistance. Molecular markers and multi-gene signatures to predict response to AIs, clinical trials aimed at preventing or overcoming resistance by combining AIs with novel targeted agents (including AI combinations with HER2, EGFR, mTOR, PI3K, Akt, CDK4/6, FGFR, HDAC, IGF-1, Src, proteosome- and angiogenic- targeting agents) A review of the effects and clinical indications of aromatase inhibitors beyond breast cancer. Many of the chapters provide extensive historical overviews to connect current knowledge with the history and inner logic of the field. The authors' team includes world-leading experts, making the book an essential resource for scientists developing new treatments for breast cancer and for medics treating breast cancer patients with aromatase inhibitors.
650 2 4 $a Drug Resistance. $3 836316
650 2 4 $a Molecular Medicine. $3 890952
650 0 $a Aromatase $x Antagonists $x Therapeutic use. $3 2145161
650 0 $a Drug resistance in cancer cells. $3 658434
650 0 $a Breast $x Cancer $x Chemotherapy. $3 900056
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Cancer Research. $3 891172
700 1 $a Larionov, Alexey. $3 2145160
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 2130880
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-17972-8
950 $a Biomedical and Life Sciences (Springer-11642)